Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 186

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

In Chronic Nephropathies Prolonged ACE Inhibition Can Induce Remission: Dynamics of Time-Dependent Changes in GFR

RUGGENENTI, PIERO, PERNA, ANNALISA, BENINI, ROBERTO, BERTANI, TULLIO, ZOCCALI, CARMINE, MAGGIORE, QUIRINO, SALVADORI, MAURIZIO, REMUZZI, GIUSEPPE·1999·Journal of the American Society of Nephrology

Abstract

Abstract.: The Ramipril Efficacy in Nephropathy Core and Follow-Up Study found that ≥36 mo of continued ramipril therapy decreased substantially the risk of end-stage renal failure (ESRF) in patients with chronic nephropathies and a urinary protein excretion rate ≥3 g/24 h. This study investigates the time-dependent changes in GFR in these patients and in control subjects who were randomized to conventional therapy during the Core period and switched to ramipril during the Follow-Up study. Analyses included 150 patients (continued ramipril: n = 74; switched to ramipril: n = 76) who had at least three GFR measurements (including baseline) during the whole observation period and a subgroup of 43 patients (continued ramipril: n = 26; switched to ramipril: n = 17) who had at least six GFR measurements, including at least three on the Core and at least three on the Follow-Up study. Ramipril (1.25 to 5 mg/d) and conventional therapy were targeted at achieving a diastolic BP below 90 mmHg. The main efficacy variables were GFR and ESRF (need for dialysis). Analysis was by intention to treat. Throughout the study, the mean ± SEM rate of GFR decline (ΔGFR) was significantly lower in patients continued on ramipril compared to those switched to ramipril (0.51 ± 0.09 versus 0.76 ± 0.10 ml/min per 1.73 m 2 per mo, P < 0.03). In patients on continued ramipril who had at least six GFR measured—but not in control subjects—ΔGFR progressively improved with time and, in the cohort with the longest follow-up, decreased from (in ml/min per 1.73 m 2 per mo): 0.16 ± 0.12 (at 18 mo) to 0.10 ± 0.05 (at 60 mo). This rate was about 10-fold slower compared to patients on conventional therapy during the REIN Core study. Analyses of the individual slopes found that at the end of the follow-up, 10 of 26 patients on continued ramipril therapy had a positive ΔGFR and another 10 patients had an improvement of ΔGFR while on ramipril therapy. ΔGFR significantly improved in parallel with a significant reduction in proteinuria. Changes in ΔGFR (P = 0.0001) and proteinuria (P = 0.04) were significantly different in the two groups. Baseline characteristics and changes in systolic and diastolic BP and 24-h urine urea and sodium excretion were comparable. The present results offer evidence that in chronic nephropathies, the tendency of GFR to decline with time can be effectively halted, even in patients with remarkably severe disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.v105997

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 186

Metadata

Authors
RUGGENENTI, P., PERNA, A., BENINI, R., BERTANI, T., ZOCCALI, C., MAGGIORE, Q., SALVADORI, M., & REMUZZI, G.
Venue
Journal of the American Society of Nephrology
Published
1999-05
Volume
10
Issue
5
Pages
997-1006
ISSN
1046-6673 (ISSN-L)
OpenAlex
W1931208941
Cited by
186
References
1
FWCI
10.59
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In Chronic Nephropathies Prolonged ACE Inhibition Can Induce Remission: Dynamics of Time-Dependent Changes in GFR. https://app.cochat.ai/papers/10.1681/asn.v105997
The paper
RUGGENENTI, P., PERNA, A., BENINI, R., BERTANI, T., ZOCCALI, C., MAGGIORE, Q., SALVADORI, M., & REMUZZI, G. (1999). In Chronic Nephropathies Prolonged ACE Inhibition Can Induce Remission: Dynamics of Time-Dependent Changes in GFR. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.v105997

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.